Early identification of non-responding locally advanced breast tumors receiving neoadjuvant chemotherapy

Martijn Van de Giessen; Boudewijn E. Schaafsma M.D.; Ayoub Charehbili M.D.; Vincent T. H. B. M. Smit M.D.; Judith R. Kroep M.D.; Boudewijn P. F. Lelieveldt M.D.; Gerrit-Jan Liefers M.D.; Alan Chan; Clemens W. G. M. Löwik; Jouke Dijkstra; Cornelis J. H. van de Velde M.D.; Martin N. J. M. Wasser M.D.; Alexander L. Vahrmeijer M.D.

doi:10.1117/12.2078845

26 February 2015 Early identification of non-responding locally advanced breast tumors receiving neoadjuvant chemotherapy

Martijn Van de Giessen, Boudewijn E. Schaafsma M.D., Ayoub Charehbili M.D., Vincent T. H. B. M. Smit M.D., Judith R. Kroep M.D., Boudewijn P. F. Lelieveldt M.D., Gerrit-Jan Liefers M.D., Alan Chan, Clemens W. G. M. Löwik, Jouke Dijkstra, Cornelis J. H. van de Velde M.D., Martin N. J. M. Wasser M.D., Alexander L. Vahrmeijer M.D.

Author Affiliations +

Proceedings Volume 9303, Photonic Therapeutics and Diagnostics XI; 93032K (2015) https://doi.org/10.1117/12.2078845
Event: SPIE BiOS, 2015, San Francisco, California, United States

Abstract

Diffuse optical spectroscopy (DOS) may be advantageous for monitoring tumor response during chemotherapy treatment, particularly in the early treatment stages. In this paper we perform a second analysis on the data of a clinical trial with 25 breast cancer patients that received neoadjuvant chemotherapy. Patients were monitored using delayed contrast enhanced MRI and additionally with diffuse optical spectroscopy at baseline, after 1 cycle of chemotherapy, halfway therapy and before surgery.

In this analysis hemoglobin content between tumor tissue and healthy tissue of the same breast is compared on all four monitoring time points. Furthermore, the predictive power of the tumor-healthy tissue difference of HbO₂ for non-responder prediction is assessed.

The difference in HbO₂content between tumor and healthy tissue was statistically significantly higher in responding tumors than in non-responding tumors at baseline (10.88 vs -0.57 μM, P=0.014) and after one cycle of chemotherapy (6.45 vs -1.31 μM, P=0.048). Before surgery this difference had diminished. In the data of this study, classification on the HbO₂ difference between tumor and healthy tissue was able to predict tumor (non-)response at baseline and after 1 cycle with an area-under-curve of 0.95 and 0.88, respectively.

While this result suggests that tumor response can be predicted before chemotherapy onset, one should be very careful with interpreting these results. A larger patient population is needed to confirm this finding.

Citation Download Citation

Martijn Van de Giessen, Boudewijn E. Schaafsma M.D., Ayoub Charehbili M.D., Vincent T. H. B. M. Smit M.D., Judith R. Kroep M.D., Boudewijn P. F. Lelieveldt M.D., Gerrit-Jan Liefers M.D., Alan Chan, Clemens W. G. M. Löwik, Jouke Dijkstra, Cornelis J. H. van de Velde M.D., Martin N. J. M. Wasser M.D., and Alexander L. Vahrmeijer M.D. "Early identification of non-responding locally advanced breast tumors receiving neoadjuvant chemotherapy", Proc. SPIE 9303, Photonic Therapeutics and Diagnostics XI, 93032K (26 February 2015); https://doi.org/10.1117/12.2078845

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available